financetom
Business
financetom
/
Business
/
Lamb Weston Takes A Hit From High Manufacturing Costs And Softer Volumes, Expects Challenging Conditions Till 2026
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lamb Weston Takes A Hit From High Manufacturing Costs And Softer Volumes, Expects Challenging Conditions Till 2026
Dec 19, 2024 5:32 AM

Lamb Weston Holdings, Inc. ( LW ) shares are trading lower in the premarket session on Thursday.

The company reported second-quarter adjusted earnings per share of 66 cents, missing the street view of $1.01. Quarterly sales of $1.60 billion (down 8% year-over-year) missed the analyst consensus estimate of $1.674 billion.

Volume dropped by 6 percent in the quarter due to weak global restaurant traffic and customer share losses, partially offset by gains.

Also Read: Why Is Penny Stock Canoo Falling On Thursday?

The decline also reflects the company's decision last year to exit a lower-priced, lower-margin business in Europe to manage its customer and product mix better.

"Higher-than-expected manufacturing costs and softer volumes accounted for the shortfall, while price/mix and operating expenses were broadly in line with our targets for the quarter," said CEO Tom Werner.

"In terms of the broader operating environment, we expect challenging conditions to persist through the remainder of fiscal 2025 and into fiscal 2026," he added.

Net sales for the North America segment fell 8% to $1.072 billion, while the International segment decreased 6% to $528.8 million. 

Adjusted gross profit declined by $134.9 million to $343.5 million versus the prior year quarter due to unfavorable price/mix, higher manufacturing costs per pound, and lower sales volumes.

Adjusted EBITDA declined by $95.0 million to $281.9 million compared to the prior year quarter, primarily due to lower net sales and adjusted gross profit.

As of November 24, the company had $79.0 million of cash and cash equivalents and $1.211 billion of available liquidity under its revolving credit facility.

Dividend Hike: In December 2024, the company approved an increase of $250 million in the company's existing $500 million share repurchase authorization under the program to an aggregate total of $750 million.

In addition, the board declared a quarterly dividend of 37 cents per share of Lamb Weston ( LW ) common stock, an increase of 1 cent.

The dividend is payable on February 28 to stockholders of record as of the close of business on January 31, 2025.

CEO Appointment: Lamb Weston ( LW ) announced the appointment of Michael J. Smith, currently COO, as President and CEO, effective January 3, 2025. He will also join the company's Board of Directors.

Smith succeeds Thomas P. Werner, who is stepping down but will serve in an advisory role until August 31, 2025.

Outlook: Lamb Weston ( LW ) has lowered its FY25 outlook, now expecting net sales of $6.35 billion to $6.45 billion, down from a prior outlook of $6.6 billion-$6.8 billion. The analyst consensus estimate pegs at $6.65 billion.

The company also revised its adjusted EPS projection to $3.05-$3.20, below the previous outlook of $4.15-$4.35. The street view stands at $4.20.

Price Action: LW shares are trading lower by 20.80% to $61.97 premarket at last check Thursday.

Read Next:

Quantum Computing, Rigetti, D-Wave Skyrocket Up To 300% In 5 Sessions After Google Unveils Willow Chip, But Analysts Urge Caution: ‘Not Every TikTok Guitarist Is The Next Taylor Swift'

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved